Last Updated: May 1, 2026

CLINICAL TRIALS PROFILE FOR COMBIVIR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Combivir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000887 ↗ A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 1 1969-12-31 The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus lamivudine (3TC) to HIV-positive pregnant women and their babies is safe. This study will also look at how long these drugs stay in the blood. ZDV has been given to mothers in the past to reduce the chances of passing HIV on to their babies. However, better treatments are needed to further reduce these chances and to better suit the treatment needs of mothers and their children. Taking a combination of anti-HIV drugs during pregnancy may be an answer.
NCT00000887 ↗ A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 1969-12-31 The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus lamivudine (3TC) to HIV-positive pregnant women and their babies is safe. This study will also look at how long these drugs stay in the blood. ZDV has been given to mothers in the past to reduce the chances of passing HIV on to their babies. However, better treatments are needed to further reduce these chances and to better suit the treatment needs of mothers and their children. Taking a combination of anti-HIV drugs during pregnancy may be an answer.
NCT00000888 ↗ Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 1 1969-12-31 The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth. Pregnant women who are HIV-positive are at risk of giving HIV to their babies during pregnancy or delivery. It is important to learn how to prevent HIV-positive pregnant women from giving HIV to their babies. RTV and ZDV have been shown to be safe and effective against HIV in adults. The combination of 3 anti-HIV drugs (RTV, 3TC, and ZDV) may help prevent HIV infection from mother to infant but studies are needed to determine whether they are safe and effective during pregnancy.
NCT00000888 ↗ Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 1 1969-12-31 The purpose of this study is to see if it is safe and effective to give ritonavir (RTV) plus lamivudine (3TC) plus zidovudine (ZDV) to HIV-infected pregnant women during pregnancy and to their babies after birth. Pregnant women who are HIV-positive are at risk of giving HIV to their babies during pregnancy or delivery. It is important to learn how to prevent HIV-positive pregnant women from giving HIV to their babies. RTV and ZDV have been shown to be safe and effective against HIV in adults. The combination of 3 anti-HIV drugs (RTV, 3TC, and ZDV) may help prevent HIV infection from mother to infant but studies are needed to determine whether they are safe and effective during pregnancy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Combivir

Condition Name

Condition Name for Combivir
Intervention Trials
HIV Infections 42
HIV Infection 8
HIV 5
Pregnancy 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Combivir
Intervention Trials
HIV Infections 53
Acquired Immunodeficiency Syndrome 12
Infections 10
Infection 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Combivir

Trials by Country

Trials by Country for Combivir
Location Trials
United States 277
Spain 23
Canada 18
United Kingdom 11
South Africa 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Combivir
Location Trials
California 29
Florida 20
New York 17
Pennsylvania 16
Texas 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Combivir

Clinical Trial Phase

Clinical Trial Phase for Combivir
Clinical Trial Phase Trials
Phase 4 21
Phase 3 16
Phase 2/Phase 3 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Combivir
Clinical Trial Phase Trials
Completed 52
Unknown status 4
Withdrawn 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Combivir

Sponsor Name

Sponsor Name for Combivir
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 12
Glaxo Wellcome 10
GlaxoSmithKline 8
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Combivir
Sponsor Trials
Industry 50
Other 36
NIH 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

COMBIVIR: Clinical Trials Update, Market Analysis, and Projections

Last updated: April 27, 2026

What is COMBIVIR and what clinical record does it have?

COMBIVIR is a fixed-dose combination of zidovudine (AZT) + lamivudine (3TC) for HIV-1. It was developed for antiretroviral combination therapy and reached widespread use during the late 1990s and early 2000s. Post-approval clinical activity for COMBIVIR itself is limited in public sources because the clinical evidence base is dominated by component drugs (AZT, 3TC) and by the class-wide shift to newer regimens.

What clinical trials still matter in 2024-2026?

Public trial activity for COMBIVIR-branded fixed-dose therapy is not a major driver of current clinical pipelines. The practical clinical-trials question for investors is whether COMBIVIR has ongoing studies affecting:

  • Regulatory updates (labels, dosing, safety)
  • Special populations (pregnancy, pediatrics, renal impairment)
  • Long-term safety in real-world cohorts

Across major clinical-trials registries, COMBIVIR-branded interventional trials are not prominent relative to ongoing studies of modern single-tablet regimens and integrase inhibitor-based therapy. Current HIV clinical research emphasis is on:

  • Treatment-naïve first-line regimens
  • Switch strategies to reduce toxicity and improve adherence
  • Resistance and adherence outcomes in real-world settings

Clinical implication: COMBIVIR is best treated as a legacy brand whose market outcome depends more on access policies, generic penetration, and guideline positioning than on new COMBIVIR-specific phase development.

What do HIV guidelines imply about COMBIVIR’s current role?

Contemporary guideline frameworks have largely moved away from legacy NRTI-backbones toward regimens built around agents with improved potency and durability. COMBIVIR still appears in some settings as part of historical or alternative regimens, but it is not a top-tier regimen in most current treatment algorithms.

Business implication: COMBIVIR’s future demand is likely concentrated in:

  • Low-resource markets where older ARVs remain in use
  • Programs with contracted procurement
  • Settings with formulary inertia and slower regimen turnover
  • Generic substitution rather than branded COMBIVIR

How is the market structured for COMBIVIR?

COMBIVIR’s market is dominated by the interaction of:

  • Legacy ARV demand (patients already stable on older regimens)
  • Generic substitution (lowest-cost zidovudine/lamivudine products)
  • Procurement cycles (tenders and national formularies)
  • Guideline shifts (replacement by newer fixed-dose combinations)

Market demand drivers

Demand driver Effect on COMBIVIR
Patient retention on older regimens Supports baseline volume in some geographies
Generic availability of zidovudine/lamivudine Pressures branded share and pricing
Procurement tenders (national and NGO) Can extend or accelerate volume depending on contracting
Guideline updates and regimen switching Reduces incremental demand over time

Market headwinds

  • Brand value erosion through generics
  • Regimen discontinuation in higher-income markets
  • Switch to newer combinations for improved tolerability and efficacy

What does the pricing and share reality look like?

COMBIVIR is exposed to classic legacy fixed-dose brand dynamics:

  • Branded pricing is forced down as generics take share.
  • Volume becomes a function of tender awards and formulary access rather than prescribing preference.

Commercial takeaway: branded COMBIVIR is unlikely to show meaningful growth; it is more plausible that it sustains a declining curve unless a payer or program explicitly maintains branded supply.

Regulatory and product continuity

COMBIVIR’s sustained availability depends on maintaining supply chains for a legacy fixed-dose formulation and competing with generic manufacturers of zidovudine/lamivudine.

Clinical safety considerations that affect access

Zidovudine carries known class-limiting toxicities such as hematologic adverse events (notably anemia and neutropenia). Lamivudine resistance dynamics have also shaped how the field uses NRTI combinations. These factors affect switching behavior and future retention.

Business impact: higher switch rates out of zidovudine-based therapy in guideline-concordant settings reduce COMBIVIR’s addressable pool.


Market analysis: historical trajectory and where demand can persist

Because COMBIVIR is a legacy combination, market size and growth rate are best approached as a declining installed base with episodic procurement-led fluctuations.

Where COMBIVIR can retain demand

Geography / channel Likely pattern
Public sector procurement in low- and middle-income markets Can sustain use via contracted supply
Settings with limited access to newer regimens Slower switching out of legacy NRTIs
Patients stable on zidovudine/lamivudine Lower immediate churn, but long-term erosion
Private markets in higher-income regions Typically limited due to guideline changes and generics

Where COMBIVIR is least likely to grow

  • High-income markets where newer NRTI backbones and integrase-based regimens dominate
  • Formulary systems that actively reduce regimen complexity
  • Programs targeting regimen standardization and resistance mitigation

How to project COMBIVIR: base, downside, and upside

A COMBIVIR projection is inherently scenario-driven because the key variables are procurement policy and switching rates.

Below are business-facing projections expressed as indexed demand (with branded performance linked to generic share), not as absolute revenue claims.

Projection framework

Key model variables

  • Patient switching velocity away from zidovudine-based regimens
  • Generic competitive intensity and price erosion
  • Procurement stability (continuation vs tender replacement)

Scenario projections (indexed, 2024 = 100)

Year Base case Downside case Upside case
2024 100 100 100
2025 85-90 75-80 90-95
2026 70-80 55-65 80-90
2027 60-70 45-55 75-85
2028 50-65 35-50 70-80

Interpretation

  • Base case: steady erosion from switching and tender replacement, with some retention of legacy cohorts.
  • Downside case: faster switching plus stronger tender displacement by alternative generic combinations.
  • Upside case: procurement continuity, slower switching, and relative brand persistence through contractual terms.

Branded vs generic overlay

Even if total zidovudine/lamivudine use persists, branded COMBIVIR share typically declines because generics offer lower prices with equivalent active ingredient profiles.

Indexed branded share projection Year Branded share index
2024 100
2025 80-90
2026 65-80
2028 40-65

Investment and business implications

1) Expect portfolio role as a cash sustain asset, not growth

COMBIVIR is positioned for legacy utilization rather than pipeline-driven expansion. Any value capture depends on:

  • residual branded procurement,
  • contractual supply continuity,
  • and geographic access.

2) Focus on procurement, not clinical differentiation

COMBIVIR does not have an active clinical differentiation strategy comparable to modern HIV regimens. The operational levers are:

  • tender inclusion,
  • SKU availability,
  • and pricing relative to zidovudine/lamivudine generics.

3) Monitor switching signals

Switching velocity away from zidovudine-based therapy is a primary driver of demand erosion:

  • guideline updates in procurement partner countries,
  • program-level regimen simplification,
  • and resistance management strategies that de-emphasize zidovudine backbones.

Key Takeaways

  • COMBIVIR is a legacy fixed-dose HIV combination (zidovudine/lamivudine) with limited recent COMBIVIR-branded clinical trial momentum relative to modern regimens.
  • Market demand is primarily an installed-base and procurement phenomenon, not a pipeline-led growth market.
  • Branded performance should trend down under generic substitution and guideline-driven switching, even if some legacy NRTI use persists.
  • Projection outlook: 2025-2028 demand typically declines in a band consistent with switching and tender replacement, with the highest variance driven by country procurement continuity.
  • Commercial actions should concentrate on tender strategy, supply continuity, and competitive pricing versus generic zidovudine/lamivudine.

FAQs

1) Is there meaningful new COMBIVIR-specific phase development?

Publicly visible COMBIVIR-branded clinical development is not prominent versus newer HIV regimen research priorities, so COMBIVIR’s near-term profile is driven by legacy use.

2) What is the main market risk to branded COMBIVIR?

Generic substitution and regimen switching out of zidovudine-based backbones reduce both price and share.

3) Where could COMBIVIR see relative durability?

Programs with procurement continuity and limited transition capacity to newer regimens can sustain legacy cohorts longer.

4) Does COMBIVIR compete primarily on clinical outcomes?

No. The competitive basis is price, formulary inclusion, and tender award mechanics, since clinical differentiation is not newly established for the branded product.

5) How should investors interpret projected volumes?

As indexed erosion driven by switching velocity and tender displacement rather than as growth from clinical innovation.


References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. COMBIVIR (zidovudine/lamivudine) and related search results. https://clinicaltrials.gov/
[2] World Health Organization. Consolidated guidelines for the prevention and treatment of HIV and related guidance (latest versions). https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/
[3] U.S. Food and Drug Administration. HIV/AIDS drug product labeling and drug information resources (zidovudine/lamivudine combination products). https://www.fda.gov/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.